340 results on '"Alegre, Adrián"'
Search Results
2. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
3. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
4. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
5. LibreOffice. Nociones básicas para gestión de la información (calc - writer - impress)
6. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
7. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting.
8. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
9. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
10. Gestión de comunidades virtuales en Bibliotecas. Un propuesta teórico-práctica. Ponencia inaugural del Encuentro de Bibliotecarios de Toledo 2014
11. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
12. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma
13. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
14. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma. Results of the Compassionate Use or the Expanded Access Program in Spain
15. Lupus anticoagulant hypoprothrombinemia syndrome: A case report
16. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
17. El Crossumer: la evolución del consumidor mediada por las tecnologías sociales y la hiperconectividad móvil
18. Transplant results in adults with Fanconi anaemia
19. Alfonso Alvarez-OssoRio Rivas--Eduardo Ferrer Albelda--Enrique Garcia Vargas (coords.), Pirateria y seguridad maritima en el Mediterraneo Antiguo (=SPAL Monografias XVII)
20. P-090: Immune biomarkers of survival and infectionrelated mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
21. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
22. Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
23. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
24. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
25. Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
26. Gestió documental i codi obert, dues peces d'un mateix trencaclosques
27. Los dominios semánticos marcan la nueva era de Internet
28. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
29. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment
30. Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005
31. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
32. ¿Tienen sentido las palabras clave de los artículos científicos?
33. Bibliotecas privadas de la Edad Media
34. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
35. WhatsApp (poco a poco) en la biblioteca
36. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
37. LUPUS ANTICOAGULANT HYPOPROTHROMBINEMIA SYNDROME: A CASE REPORT
38. Therapeutic efficacy of a plasma rich in growth factors gel combined with fractional ablative laser in the management of post-acne scars
39. Coste-efectividad del tratamiento de la anemia inducida por quimioterapia con agentes estimuladores de la eritropoyesis
40. Reseña de Fernando Juárez-Urquijo. Biblioteca Pública: Mientras llega el futuro.
41. Therapeutic Efficacy of a Plasma Rich in Growth Factors Gel Combined with Fractional Ablative Laser in the Management of Post-acne Scars.
42. Reseña de Los Sexenios de Investigación
43. MORA VILLAREJO, L. (ed.) Catálogo de fondo antiguo con tipografía árabe: una colección singular en la Biblioteca Islámica Félix M.ª Pareja
44. MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis
45. Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies
46. MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies
47. Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis
48. Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study
49. Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
50. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.